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Nanoscale coordination polymers containing exceptionally high loadings of bisphosphonates were
coated with single lipid bilayers to control the drug release kinetics and functionalized with a
targeting ligand to endow cell-targeting capability, leading to much enhanced cytotoxicity against
human lung and pancreatic cancer cells.
Coordination polymers are an interesting class of molecular materials that have found many
applications, including gas storage,1 catalysis,2 nonlinear optics,3 chemical sensing,4 and
separations.5 When scaled down to the nano-regime, nanoscale coordination polymers
(NCPs) have shown promise for applications in biomedical imaging.6 NCPs have also been
used to deliver chemotherapeutics to cancer cells,7 but their utility is limited by the reliance
on non-biologically compatible metal ions. We report here the synthesis of NCPs by linking
nitrogen-containing bisphosphonates (N-BPs) with Ca2+, one of the most biologically
prevalent ions, and targeted delivery of N-BPs to cancer cells with surface-modified NCPs.
N-BPs inhibit osteoclast-mediated bone resorption and are used clinically to treat patients
with osteoporosis and bone metastases of several cancers.8 Recently, N-BPs have been
shown to be effective antitumor agents, by inhibiting farnesyl pyrophosphate synthase, a key
enzyme in the biosynthetic mevalonate pathway, which in turn induces caspase-dependent
apoptosis, inhibits matrix metalloproteinase activity, and down-regulates αvβ3 and αvβ5
integrins.9 However, N-BPs are not effective anticancer drugs due to their unfavorable
pharmacokinetics, as the majority of the injected N-BP dose either binds to the bones or is
quickly cleared via renal filtration. In this work, we have incorporated two N-BPs,
pamidronate (Pam) and zoledronate (Zol), directly into crystalline NCPs using Ca2+ ions as
the metal-connecting points, and demonstrated the targeted delivery of N-BPs to cancer cells
with surface-modified NCPs (Scheme 1). The NCP formulations have several advantages,
including the crystalline nature, exceptionally high drug loadings,10 controllable
compositions, shapes, and sizes, and intrinsic biodegradability.11
A solvothermal reaction between Na2Pam and CaCl2·2H2O in diethylformamide (DEF)/
H2O afforded single crystals of Ca-Pam with the formula of [Ca(H2-Pam)(H2O)]·H2O.‡ A
similar reaction between H4-Zol and CaCl2·2H2O in dimethylformamide (DMF)/H2O gave
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single crystals of Ca-Zol with the formula of [Ca(H2-Zol)(H2O)].§ Ca-Pam and Ca-Zol are
isostructural, and adopt a 1-D polymeric structure. The Ca2+ center is coordinated by seven
oxygen atoms, one from the water molecule and the other six from the phosphonate groups,
to form a 1-D polymer (Fig. 1). The phase purity of Ca-Pam and Ca-Zol was supported by
their powder X-ray diffraction (PXRD) patterns.
Crystalline particles of Ca-Pam (1) were synthesized in 70% yield by a solvothermal
reaction between H4-Pam and CaCl2·2H2O in water. SEM and TEM images show that 1
forms rod-like particles of ~ 80 × 80 × 1000 nm in dimensions (Fig. 2a and b). Pam loading
was determined to be 75.5 wt% by UV-Vis spectroscopy via complexation with Fe3+ ions
(expected 80.0 wt%). Microwave heating of a solution of H4-Zol and CaCl2·2H2O in DMF/
H2O at 100 °C led to crystalline particles of Ca-Zol (2) which also adopts a rod-like
morphology of ~ 70 × 70 × 1000 nm in dimensions (Fig. 2d and e). 2 has a Zol loading of
75.7 wt% as measured by UV-Vis spectroscopy (expected 83.0 wt%). The synthesis of 1 and
2 is highly reproducible, and their formulations were supported by thermogravimetric
analysis (TGA). PXRD results indicated that 1 and 2 share the same phase as their bulk
crystals.
The as-synthesized particles of 1 and 2 are stable in water but decompose gradually in 5 mM
phosphate-buffered saline (PBS) solution at 37 °C with a half-life (t1/2) of 6.3 h and 15.8 h,
respectively (Fig. 2a). To slow down the dissolution of N-BPs in biologically relevant
media, we coated these particles with single lipid bilayers (SLBs) containing 1 : 1 (by mol)
DOTAP/DOPE (DOTAP = dioleoyl trimethylammonium propane and DOPE = dioleoyl L-α-
phosphatidylethanolamine). The SLBs not only stabilize the particles but also impart
biocompatibility.12 Liposomes of 100–110 nm in diameter with a ζ potential of 55 ± 10 mV
were mixed with 1 or 2 in 10 mM aq. KCl with a particle:liposome weight ratio of 4 : 1 to
afford lipid-coated NCPs. The presence of SLBs was confirmed by dynamic light scattering
(DLS) measurements, TGA, TEM, and N-BP release data. Whereas the as-synthesized
particles possess negative ζ potentials (−22.1 ± 2 mV for 1 and −32.5 ± 2 mV for 2),
1@lipid and 2@lipid have ζ potential values of 54.4 ± 6 mV and 56.2 ± 4 mV, respectively.
TGA gave 8–10 wt% additional organic weight loss in the 200–500 °C temperature range
for the lipid coating. Coverage of individual particles with SLBs was supported by TEM
studies using uranyl acetate stain. Dark rings were observed around the lipid-coated NCP
particles due to the interaction between uranyl ions and the phosphate groups of DOPE (Fig.
2c and f). Drug loadings after lipid coating were determined to be 65.1 wt% and 67.0 wt%
for 1@lipid and 2@lipid, respectively. The release profiles for 1@lipid and 2@lipid in 5
mM PBS at 37 °C gave a t1/2 of 20.1 h and 37.7 h, with complete release achieved in 120 h
and 140 h, respectively. The initial burst release of the cargoes (Fig. 3a and b) probably
results from the uncoated or incompletely coated particles (Table 1).
Anisamide (AA) was conjugated to DOPE via the primary amine group as the targeting
ligand because AA is known to target σ receptors that are overexpressed by many human
cancer cells, including H460 human non-small cell lung cancer cells and AsPC-1 human
pancreatic cancer cells.13 10 mol% of DOPE-AA was incorporated into the liposomal
formulation, and the resulting 1@lipid-AA and 2@lipid-AA had similar sizes, drug
loadings, and ζ potentials as their undoped counterparts (Fig. 3c and d).
‡Crystal data for Ca-Pam: Orthorhombic, Pna21, a = 13.749(1) Å, b = 10.609(1) Å, c = 6.923(1) Å, V = 1009.8(1) Å3, ρcalc = 1.994
g cm−3. R1 = 0.036, wR2 = 0.095.
§Crystal data for Ca-Zol: Orthorhombic, Pna21, a = 13.483(1) Å, b = 12.696(1) Å, c = 6.764(1) Å, V = 1157.8(1) Å3, ρcalc = 1.860 g
cm−3. R1 = 0.059, wR2 = 0.143.
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We performed in vitro cytotoxicity assays on H460 cells. The free drug and as-synthesized
NCPs 1 and 2 do not lead to any appreciable cell death, as a result of their inability to enter
the cells. However, 1@lipid and 2@lipid showed significantly higher potency, with IC50
(50% inhibitory concentration) values of 4.5 ± 3.4 and 1.0 ± 0.5 µM, respectively. 1@lipid-
AA and 2@lipid-AA have slightly lower IC50 values of 1.0 ± 0.1 and 0.84 ± 0.2 µM,
respectively. Lipid-coated and AA-targeted NCPs can thus be effectively internalized by
cells, presumably via fusion of the cationic lipid bilayers with cell membranes and σ
receptor-mediated endocytosis. We also performed in vitro cytotoxicity assays on AsPC-1
cells. No cell death was observed for Pam, 1, 1@lipid, and 1@lipid-AA, indicating that
Pam does not induce apoptosis in AsPC-1 cells. However, 2@lipid and 2@lipid-AA gave
IC50 values of 6.9 ± 1.4 and 3.6 ± 2.3 µM, respectively. The inability of 1@lipid and
1@lipid-AA to induce apoptosis in AsPC-1 cells provides convincing evidence that the N-
BPs, not Ca2+ ions, are responsible for the observed cytotoxicity.
The targeting capability of the NCPs was further supported by laser scanning confocal
fluorescence microscopy studies. 5 mol% DOPE-rhodamine was doped into the liposomal
formulation for imaging studies. The cells were also stained with DRAQ5 nuclear stain and
Annexin V-FITC apoptosis marker. As shown in Fig. 4, significant fluorescence from
rhodamine (red) and FITC (green) was observed in the confocal z section images of H460
cells incubated with 1@lipid-AA, indicating increased apoptosis due to enhanced cell uptake
of the targeted particles. In comparison, much weaker red and green signals were observed
for H460 cells incubated with 1@lipid.
In summary, we have developed a general strategy to deliver bisphosphonates to cancer cells
by incorporation into crystal-line NCPs at exceptionally high drug loadings. Lipid-coated
and anisamide-targeted NCPs displayed superior anti-tumor efficacy compared to the as-
synthesized particles or free bisphosphonates in vitro against human lung and pancreatic
cancer cells. NCPs thus provide a generalized approach for delivering otherwise ineffective
chemotherapeutics with unfavorable pharmacokinetics to cancer cells.
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Side view of the 1-D polymeric structure of Ca-Pam (a) and Ca-Zol (c). Packing diagram
of Ca-Pam (b) and Ca-Zol (d) as viewed down the c axis. Ca: green; P: pink; N: blue; C:
gray; O: red. Hydrogen atoms are omitted for clarity.
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(a) SEM and (b) TEM image of 1. (c) TEM image of 1-lipid with uranyl stain. (d) SEM and
(e) TEM images of 2. (f) TEM image of 2-lipid with uranyl stain.
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Release profiles of 1 and 1@lipid (a) and 2 and 2@lipid (b) in PBS at 37 °C. In vitro
cytotoxicity assays of various Pam (c) and Zol (d) formulations against H460 cells. Error
bars represent one standard deviation.
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Fluorescence images of H460 cells incubated with no particles (a, d, g), 1@lipid (b, e, h),
and 1@lipid-AA (c, f, i). Channels are: DRAQ5 nuclear stain (purple), Annexin V FITC
conjugate early apoptosis stain (green), and DOPE-rhodamine from the particles (red). Scale
bars are 40 µm.
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Synthesis and surface functionalization of NCPs and their targeted delivery to cancer cells.
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Table 1










1 −22.1 ± 2 75.5 13.0 ± 12.0 > 20
1 lipid 54.5 ± 6 65.1 4.5 ±3.4 > 20
1 lipid-AA 55.3 ±6 66.3 1.0 ± 0.1 > 20
2 −32.5 ± 2 75.7 > 5.0 > 10
2 lipid 56.2 ± 4 67.0 1.0 ± 0.5 6.9 ± 1.4
2 lipid-AA 55.1 ± 3 69.3 0.84 ± 0.2 3.6 ± 2.3
a
Values in 10 mM aq. KCl.
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